Sascha Weggen

7.9k citations

93 papers · 6.2k indexed · 2 hit papers · h-index 40

Physiology top 0.2%
Molecular Biology top 5%
Pharmacology top 0.5%
Neurology top 0.5%
Computational Theory and Mathematics top 0.5%

Co-authors: Claus U. Pietrzik Edward H. Koo Jason L. Eriksen Todd E. Golde Sarah A. Sagi Pritam Das Victor Ozols Thomas A. Bayer
Topics: Alzheimer's disease research and treatments (60 papers)Cholinesterase and Neurodegenerative Diseases (16 papers)Drug Transport and Resistance Mechanisms (15 papers)
Cited by: Biological Psychiatry Physiology Neurology
Journals: Nature Proceedings of the National Academy of Sciences Journal of Biological Chemistry
Partner nations: Germany United States Switzerland

In The Last Decade

Sascha Weggen

93 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity

2001 1.1k citations Sascha Weggen, Jason L. Eriksen et al. profile →
NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo

2003 502 citations Jason L. Eriksen, Sarah A. Sagi et al. Journal of Clinical Investigation profile →

Peers

Countries citing papers authored by Sascha Weggen

Since Specialization

Citations

This map shows the geographic impact of Sascha Weggen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sascha Weggen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sascha Weggen more than expected).

Fields of papers citing papers by Sascha Weggen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sascha Weggen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sascha Weggen. The network helps show where Sascha Weggen may publish in the future.

Co-authorship network of co-authors of Sascha Weggen

This figure shows the co-authorship network connecting the top 25 collaborators of Sascha Weggen. A scholar is included among the top collaborators of Sascha Weggen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sascha Weggen. Sascha Weggen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Antibody‐mediated inhibition of tissue‐type plasminogen activator binding to the low‐density lipoprotein receptor‐related protein 1 as a potential beneficial modulator for stroke therapy 2023 ·Journal of Cellular Biochemistry ·(unknown),(unknown),(unknown),Sascha Weggen,Claus U. Pietrzik	2
2	Brain Region-Specific Differences in Amyloid-β Plaque Composition in 5XFAD Mice 2023 ·Life ·(unknown),(unknown),(unknown),(unknown),(unknown),Hans‐Wolfgang Klafki,Thomas Meyer,Olaf Jahn,Sascha Weggen,Oliver Wirths	11
3	Progranulin prevents regulatory NK cell cytotoxicity against antiviral T cells 2019 ·JCI Insight ·Anfei Huang,Prashant V. Shinde,Jun Huang,Tina Senff,Haifeng C. Xu,(unknown),Dieter Häussinger,Thomas E. Willnow,Jinping Zhang,Aleksandra A. Pandyra,Jörg Timm,Sascha Weggen,Karl S. Lang,Philipp A. Lang	9
4	Discovery and validation of 2-styryl substituted benzoxazin-4-ones as a novel scaffold for rhomboid protease inhibitors 2018 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Thorsten Jumpertz,(unknown),Isabella Ogorek,David C. Mikles,Martin Hubálek,Claus U. Pietrzik,Kvido Střı́šovský,Boris Schmidt,Sascha Weggen	16
5	Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia 2018 ·Acta Neuropathologica Communications ·Melanie Hüttenrauch,Isabella Ogorek,Hans‐Wolfgang Klafki,Markus Otto,Christine Stadelmann,Sascha Weggen,Jens Wiltfang,Oliver Wirths	96
6	The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM 2018 ·Brain Behavior and Immunity ·Steffen E. Storck,Anika M. S. Hartz,Jessica K. Bernard,Andrea Wolf,(unknown),Anne Mahringer,Sascha Weggen,Jens Pahnke,Claus U. Pietrzik	104
7	Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood–brain barrier model 2013 ·Alzheimer s Research & Therapy ·(unknown),(unknown),Julia Stäb,Dominic Docter,Sandra Baches,Roland H. Stauber,Mordechai Deutsch,Reinhold Schmidt,Stefan Ropele,Manfred Windisch,Klaus Langer,Sylvia Wagner,Hagen von Briesen,Sascha Weggen,Claus U. Pietrzik	52
8	Stx5 is a novel interactor of VLDL-R to affect its intracellular trafficking and processing 2013 ·Experimental Cell Research ·(unknown),Marco Dieckmann,Sébastian Jaeger,Sascha Weggen,Claus U. Pietrzik	12
9	LRP1 is critical for the surface distribution and internalization of the NR2B NMDA receptor subtype 2013 ·Molecular Neurodegeneration ·(unknown),Mariola Bednorz,(unknown),Anton Roebroek,Sascha Weggen,Ulrich Schmitt,Claus U. Pietrzik	46
10	The Metalloprotease Meprin β Generates Amino Terminal-truncated Amyloid β Peptide Species 2012 ·Journal of Biological Chemistry ·(unknown),(unknown),Mirsada Čaušević,Thorsten Jumpertz,Lisa Marie Munter,Gerd Multhaup,Sascha Weggen,Christoph Becker‐Pauly,Claus U. Pietrzik	107
11	Presenilin Is the Molecular Target of Acidic γ-Secretase Modulators in Living Cells 2012 ·PLoS ONE ·Thorsten Jumpertz,Andreas Rennhack,(unknown),Sandra Baches,Claus U. Pietrzik,Bruno Bulic,Sascha Weggen	36
12	Autoreactive‐Aβ antibodies promote APP β‐secretase processing 2011 ·Journal of Neurochemistry ·Juan Deng,Huayan Hou,Brian Giunta,Takashi Mori,Yan‐Jiang Wang,Frank Fernandez,Sascha Weggen,Wataru Araki,Demian Obregon,Jun Tan	23
13	Amyloid beta 42 peptide (Aβ42)-lowering compounds directly bind to Aβ and interfere with amyloid precursor protein (APP) transmembrane dimerization 2010 ·Proceedings of the National Academy of Sciences ·(unknown),Lisa Marie Munter,(unknown),Peter W. Hildebrand,Muralidhar Dasari,(unknown),Bruno Bulic,Michael Beyermann,Ronald Gust,Bernd Reif,Sascha Weggen,Dieter Langosch,Gerd Multhaup	91
14	Exploring the chemical space of γ-secretase modulators 2010 ·Trends in Pharmacological Sciences ·Heiko Zettl,Sascha Weggen,Petra Schneider,Gisbert Schneider	24
15	Inactivation of the proximal NPXY motif impairs early steps in LRP1 biosynthesis 2009 ·Cellular and Molecular Life Sciences ·(unknown),Thorsten Pflanzner,Philip L.S.M. Gordts,(unknown),Pascale Zimmermann,Wim Annaert,Sascha Weggen,Anton Roebroek,Claus U. Pietrzik	26
16	Formation of Pmel17 Amyloid Is Regulated by Juxtamembrane Metalloproteinase Cleavage, and the Resulting C-terminal Fragment Is a Substrate for γ-Secretase 2008 ·Journal of Biological Chemistry ·Markus P. Kummer,(unknown),(unknown),Sandra Baches,Sascha Weggen,Edward H. Koo	50
17	The Functional Role of the Second NPXY Motif of the LRP1 β-Chain in Tissue-type Plasminogen Activator-mediated Activation of N-Methyl-D-aspartate Receptors 2008 ·Journal of Biological Chemistry ·(unknown),Christoph Kuhlmann,Svenja V. Trossbach,Sébastian Jaeger,Elaine Waldron,Anton Roebroek,Heiko J. Luhmann,A. Laatsch,Sascha Weggen,Volkmar Leßmann,Claus U. Pietrzik	86
18	Inhibitors of Rho‐kinase modulate amyloid‐β (Aβ) secretion but lack selectivity for Aβ42 2005 ·Journal of Neurochemistry ·Stefanie Leuchtenberger,Markus P. Kummer,Thomas Kukar,Eva Czirr,Nicole Teusch,Sarah A. Sagi,Rebecca Berdeaux,Claus U. Pietrzik,Thomas B. Ladd,Todd E. Golde,Edward H. Koo,Sascha Weggen	26
19	Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production 2005 ·Nature Medicine ·Thomas Kukar,M. Paul Murphy,Jason L. Eriksen,Sarah A. Sagi,Sascha Weggen,(unknown),Thomas B. Ladd,Murad Ali Khan,Rajashaker Kache,(unknown),Mark Dodson,(unknown),Victor Ozols,Panos Z. Anastasiadis,Pritam Das,Abdul H. Fauq,Edward H. Koo,Todd E. Golde	228
20	NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivobreakdown → 2003 ·Journal of Clinical Investigation ·Jason L. Eriksen,Sarah A. Sagi,(unknown),Sascha Weggen,Pritam Das,(unknown),Victor Ozols,(unknown),Kenton H. Zavitz,Edward H. Koo,Todd E. Golde	502

About Sascha Weggen

Sascha Weggen is a scholar working on Biological Psychiatry, Physiology and Neurology, having authored 93 papers that have together received 6.2k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (60 papers), Cholinesterase and Neurodegenerative Diseases (16 papers) and Drug Transport and Resistance Mechanisms (15 papers). The work is most often cited by research in Biological Psychiatry (391 citations), Physiology (3.8k citations) and Neurology (1.1k citations). Sascha Weggen has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Claus U. Pietrzik, Edward H. Koo, Jason L. Eriksen, Todd E. Golde, Sarah A. Sagi, Pritam Das, Victor Ozols, Thomas A. Bayer, Dirk Beher and Sandra Baches. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact